Latest Strategy News

Bastion Minerals has successfully placed the entire shortfall from its recent entitlement offer, raising $263,530 and underscoring strong shareholder support for its exploration strategy.

Lowell Resources Fund updates its estimated FY25 dividend to AUD 0.0274 per unit with a partly franked component, alongside a revised distribution reinvestment plan price at a 10% discount.

Yowie Group has decided not to proceed with its planned takeover bid for Keybridge Capital after a key condition was triggered, signaling a strategic retreat.

Echo IQ has secured a pivotal reseller agreement with US-based SARC MedIQ, unlocking access to over 300 healthcare facilities and accelerating adoption of its AI-driven EchoSolv AS technology across the American cardiology landscape.

Brightstar Resources has launched its second phase of drilling at the Yunndaga deposit, aiming to expand and refine its gold resource as part of a fast-tracked development plan at the Menzies Hub.

Yowie Group has appointed Jesse Hamilton as its new Company Secretary, following the resignation of John Patton. The company also confirmed the automatic termination of executive roles held by former directors Nicholas Bolton and John Patton.

Whitefield Income Limited reported a steady net tangible asset backing of $1.26 per share for June 2025, alongside a robust fully franked dividend yield of 7.4%, maintaining its appeal to income-focused investors.

Manuka Resources has boosted the net present value of its Cobar Basin silver and gold project to A$153 million, driven by higher commodity prices, while advancing financing talks and exploring a Mt Boppy open pit cut-back to enhance production.

Aguia Resources has scrapped its planned convertible note issue, converting $750,000 in subscriptions into a secured loan with a potential share conversion feature, pending shareholder approval.

Neurizon Therapeutics has received positive feedback from the FDA on its plan to resolve the clinical hold on its ALS drug candidate NUZ-001, with key preclinical studies completed ahead of schedule. The company aims to resume clinical trials in late 2025.

Imricor Medical Systems has secured key European regulatory approvals for its second-generation NorthStar system and initiated its commercial launch, while US FDA submissions progress amid some delays.

Australian Rare Earths Limited (ASX, AR3) has acquired exploration license EL6895, adding 972 km² to its Overland Uranium Project and uncovering significant near-surface uranium potential from historic data. Drilling is set to resume in July 2025 to test this promising new target alongside existing deeper uranium prospects.